US OptionsDetailed Quotes
MCRB241220P2000
- 0.00
- 0.000.00%
15min DelayClose Dec 30 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV-140.96%PremiumDec 20, 2024Expiry Date1.17Intrinsic Value100Multiplier-10DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Seres Therapeutics Stock Discussion
Sign in to post a comment
$Seres Therapeutics (MCRB.US)$ may this fly later. (:
1
$Seres Therapeutics (MCRB.US)$ Reuters· 3 mins ago
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ Ser-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ Ser-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)
$Seres Therapeutics (MCRB.US)$
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial bloodstream infections versus placebo
Breakthrough Therapy meeting with FDA on next study of SER-155 in allo-HSCT expected in Q1 2025
Ser...
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics' SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial bloodstream infections versus placebo
Breakthrough Therapy meeting with FDA on next study of SER-155 in allo-HSCT expected in Q1 2025
Ser...
No comment yet
flabbyduck OP : let's wait for people to jump from ldtc to this. come onnn